A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment

Arquivos De Gastroenterologia
Patrícia Coelho de SoárezMarcos Bosi Ferraz

Abstract

Experimental and clinical studies suggest that LOLA may have a favorable influence on hepatic encephalopathy due to the effect on the reduction of ammonia, and improvement of the symptoms and laboratory findings. To evaluate and to critically analyze the efficacy and/or effectiveness results of the use of LOLA when compared to placebo in the treatment of hepatic encephalopathy. LILACS, SciELO, MEDLINE, PubMed database and Cochrane Collaboration Register of Controlled Trials were searched from 1966 to September of 2006. The review has included all the randomized controlled double-blind clinical trials performed in humans in English language. Four studies published between 1993 and 2000 were selected and reviewed. LOLA was showed as being able to reduce hyperammonemia in patients with hepatic encephalopathy, when compared to patients in the placebo group. Although the trials have shown efficacy of LOLA in reducing hyperammonemia of hepatic encephalopathy, sufficient evidence of a significant beneficial effect of LOLA on patients with hepatic encephalopathy was not found. The studies performed in this area were small, with short follow-up periods and half of them showed low methodological quality.

References

Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Oct 1, 1996·Alimentary Pharmacology & Therapeutics·R JalanS D Taylor-Robinson
Aug 1, 1996·Seminars in Liver Disease·J C Quero, S W Schalm
Jun 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G KircheisS Stauch
Jul 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M GroenewegS W Schalm
Aug 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C RoseR F Butterworth
Dec 18, 2001·Journal of Neuroscience Research·P DesjardinsR F Butterworth
Dec 11, 2002·Journal of Gastroenterology and Hepatology·Gerald Kircheis, Dieter Häussinger
Jan 31, 2003·Gastroenterology·Karin WeissenbornMartin Caselitz
Feb 27, 2003·Metabolic Brain Disease·Roger F Butterworth
Feb 27, 2003·Metabolic Brain Disease·G KircheisD Häussinger
Sep 3, 2003·Liver International : Official Journal of the International Association for the Study of the Liver·Roger F Butterworth
Jun 1, 1964·Japanese Journal of Pharmacology·A SHIOYAY TAMAMA
Dec 16, 2003·Deutsche medizinische Wochenschrift·M Wettstein, D Häussinger
Mar 5, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christian WeinPeter Schauder
Mar 22, 2005·Journal of Hepatology·María OrtizJuan Córdoba
May 28, 2005·Metabolic Brain Disease·Josef Finsterer, Elisabeth Bernauer
Aug 4, 2005·Biomedical Chromatography : BMC·P KowalskiH Lamparczyk

❮ Previous
Next ❯

Citations

Jan 1, 2012·Computational and Structural Biotechnology Journal·Ahmed ZahoorVolker F Wendisch
Feb 1, 2018·Nutrients·Jing LiuSeong-Tshool Hong
May 16, 2018·The Cochrane Database of Systematic Reviews·Ee Teng GohMarsha Y Morgan
Nov 19, 2013·Expert Review of Gastroenterology & Hepatology·Jonathan P Sturgeon, Debbie L Shawcross

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.